10-Q 1 mrk-20210930.htm 10-Q mrk-20210930
FALSE2021Q3000031015812/310.100003101582021-01-012021-09-300000310158us-gaap:CommonStockMember2021-01-012021-09-300000310158mrk:A0.500Notesdue2024Member2021-01-012021-09-300000310158mrk:A1.875Notesdue2026Member2021-01-012021-09-300000310158mrk:A2.500Notesdue2034Member2021-01-012021-09-300000310158mrk:A1.375Notesdue2036Member2021-01-012021-09-30xbrli:shares00003101582021-10-31iso4217:USD00003101582021-07-012021-09-3000003101582020-07-012020-09-3000003101582020-01-012020-09-30iso4217:USDxbrli:shares00003101582021-09-3000003101582020-12-3100003101582019-12-3100003101582020-09-300000310158mrk:OrganonCoMember2021-06-0200003101582021-06-020000310158srt:MaximumMembermrk:TransitionServicesAgreementMember2021-06-022021-06-020000310158mrk:ManufacturingAndSupplyAgreementsMembersrt:MinimumMember2021-06-022021-06-020000310158srt:MaximumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158mrk:OrganonCoMember2021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-022021-06-020000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-06-022021-06-020000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-022021-06-020000310158us-gaap:AdditionalPaidInCapitalMember2021-06-022021-06-020000310158us-gaap:RestrictedStockUnitsRSUMember2021-06-020000310158us-gaap:PerformanceSharesMember2021-06-02xbrli:pure0000310158mrk:OrganonCoMember2021-06-022021-06-020000310158mrk:AcceleronPharmaIncMembersrt:ScenarioForecastMember2021-12-310000310158mrk:AcceleronPharmaIncMembersrt:ScenarioForecastMember2021-10-012021-12-310000310158mrk:AcceleronPharmaIncMembersrt:ScenarioForecastMembersrt:MinimumMember2021-12-310000310158srt:MaximumMembermrk:AcceleronPharmaIncMembersrt:ScenarioForecastMember2021-12-310000310158mrk:PandionTherapeuticsMember2021-04-012021-04-300000310158mrk:PandionTherapeuticsMember2021-04-300000310158mrk:PandionTherapeuticsMember2021-01-012021-09-300000310158mrk:OralAndInjectableFormulationsMembermrk:GileadSciencesMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-012021-03-310000310158mrk:GileadSciencesMembermrk:OralFormulationMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-012021-03-310000310158mrk:GileadSciencesMembermrk:InjectableFormulationMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-012021-03-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMembermrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMember2021-01-012021-01-310000310158mrk:SalesBasedMilestonesMembermrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembersrt:MinimumMember2021-01-012021-01-310000310158srt:MaximumMembermrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:OncoImmuneMember2020-12-012020-12-310000310158mrk:OncoImmuneMember2020-12-310000310158mrk:OncoImmuneMember2020-01-012020-12-310000310158mrk:COVID19Member2021-01-012021-09-300000310158mrk:SeagenMember2020-09-012020-09-300000310158mrk:SeagenMember2020-09-300000310158mrk:SeagenMember2020-07-012020-09-300000310158mrk:SeagenMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2020-09-012020-09-3000003101582020-10-012020-10-310000310158mrk:DevelopmentMilestonesMembermrk:SeagenMember2020-09-012020-09-300000310158mrk:SalesBasedMilestonesMembermrk:SeagenMember2020-09-012020-09-300000310158mrk:TukysaMembermrk:SeagenMember2020-07-012020-09-300000310158mrk:TukysaMembermrk:SeagenMember2020-01-012020-09-300000310158mrk:TukysaMembermrk:SeagenMembermrk:RegulatoryMilestonesMember2020-09-012020-09-300000310158mrk:TukysaMembermrk:SeagenMembersrt:MinimumMember2020-09-012020-09-300000310158srt:MaximumMembermrk:TukysaMembermrk:SeagenMember2020-09-012020-09-30iso4217:EUR0000310158mrk:DunboyneMember2020-09-012020-09-300000310158mrk:DunboyneMember2020-09-300000310158mrk:SentinelMember2020-07-012020-07-310000310158mrk:SentinelMemberus-gaap:DevelopedTechnologyRightsMember2020-07-012020-07-310000310158mrk:SentinelMember2020-07-310000310158mrk:SentinelMemberus-gaap:DevelopedTechnologyRightsMember2020-07-012020-07-310000310158mrk:ThemisMember2020-06-012020-06-300000310158mrk:ThemisMember2020-06-300000310158mrk:ThemisMembermrk:COVID19Member2020-10-012020-12-310000310158mrk:ThemisMember2020-01-012020-12-310000310158mrk:DevelopmentMilestonesMembermrk:ThemisMember2020-12-310000310158mrk:ThemisMembermrk:RegulatoryMilestonesMember2020-12-310000310158mrk:SalesBasedMilestonesMembermrk:ThemisMember2020-12-310000310158mrk:ArQuleMember2020-01-012020-01-310000310158mrk:ArQuleMember2020-01-310000310158mrk:ArQuleMember2020-01-160000310158mrk:ArQuleMemberus-gaap:MeasurementInputDiscountRateMember2020-01-160000310158mrk:AstraZenecaMembermrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-09-300000310158mrk:LynparzaMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:AlliancerevenueLynparzaMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:AlliancerevenueLynparzaMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:AlliancerevenueLynparzaMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:AlliancerevenueLynparzaMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-09-300000310158mrk:AstraZenecaMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2020-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-12-310000310158mrk:EisaiMember2021-03-012021-03-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-09-300000310158mrk:EisaiMembermrk:LenvimaMembermrk:RegulatoryMilestonesMember2021-07-012021-09-300000310158mrk:LenvimaMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-09-300000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2020-12-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2020-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2021-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2020-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-03-310000310158mrk:VerquvoMember2021-01-012021-09-300000310158mrk:AdempasMemberus-gaap:OtherIntangibleAssetsMember2021-09-300000310158us-gaap:OtherIntangibleAssetsMembermrk:VerquvoMember2021-09-300000310158us-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-07-012021-09-300000310158us-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-01-012021-09-300000310158us-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158mrk:AdempasMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-07-012021-09-300000310158mrk:AdempasMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158mrk:AdempasMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-01-012021-09-300000310158mrk:AdempasMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:SalesMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:SalesMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2021-09-300000310158us-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-12-310000310158us-gaap:CollaborativeArrangementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:BayerAGMember2021-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:BayerAGMember2020-12-310000310158srt:ScenarioForecastMember2021-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OtherRestructuringMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OtherRestructuringMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OtherRestructuringMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OtherRestructuringMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OtherRestructuringMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2020-07-012020-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2020-07-012020-09-300000310158us-gaap:RestructuringChargesMember2020-07-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2020-01-012020-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2020-01-012020-09-300000310158us-gaap:RestructuringChargesMember2020-01-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158mrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMember2020-07-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158mrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMember2020-01-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2020-12-310000310158mrk:AcceleratedDepreciationMember2020-12-310000310158us-gaap:OtherRestructuringMember2020-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2021-09-300000310158mrk:AcceleratedDepreciationMember2021-09-300000310158us-gaap:OtherRestructuringMember2021-09-300000310158srt:MaximumMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000310158srt:MaximumMemberus-gaap:NondesignatedMember2021-01-012021-09-300000310158us-gaap:ForeignExchangeContractMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMember2020-07-012020-09-300000310158us-gaap:ForeignExchangeContractMember2021-01-012021-09-300000310158us-gaap:ForeignExchangeContractMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000310158mrk:EurodominatedNotesMember2021-07-012021-09-300000310158mrk:EurodominatedNotesMember2020-07-012020-09-300000310158mrk:EurodominatedNotesMember2021-01-012021-09-300000310158mrk:EurodominatedNotesMember2020-01-012020-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-07-012020-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-09-30mrk:interest_rate_swap0000310158us-gaap:InterestRateSwapMember2021-01-310000310158mrk:A3.875NotesDue2021Member2021-01-310000310158us-gaap:InterestRateSwapMember2021-09-300000310158us-gaap:InterestRateSwapMembermrk:A2.40NotesDue2022Member2021-09-300000310158mrk:A2.35NotesDue2022Memberus-gaap:InterestRateSwapMember2021-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2021-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2020-12-310000310158mrk:LongTermDebtExcludingCurrentMaturitiesMember2021-09-300000310158mrk:LongTermDebtExcludingCurrentMaturitiesMember2020-12-310000310158us-gaap:OtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:OtherCurrentAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:OtherAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:OtherAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2021-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000310158us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-09-300000310158us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-12-310000310158us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-09-300000310158us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-12-310000310158us-gaap:NondesignatedMember2021-09-300000310158us-gaap:NondesignatedMember2020-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2021-01-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2020-01-012020-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2021-07-012021-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2021-01-012021-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000310158us-gaap:InterestRateSwapMember2021-07-012021-09-300000310158us-gaap:InterestRateSwapMember2020-07-012020-09-300000310158us-gaap:InterestRateSwapMember2021-01-012021-09-300000310158us-gaap:InterestRateSwapMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2021-01-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2020-01-012020-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2021-07-012021-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2020-07-012020-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2021-01-012021-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2021-01-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2020-01-012020-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000310158us-gaap:CorporateDebtSecuritiesMember2021-09-300000310158us-gaap:CorporateDebtSecuritiesMember2020-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2021-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2021-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2020-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2020-12-310000310158us-gaap:FairValueInputsLevel2Member2021-09-300000310158us-gaap:FairValueInputsLevel2Member2020-12-310000310158mrk:SanofiPasteurMember2021-09-300000310158mrk:SanofiPasteurMember2020-12-310000310158mrk:SanofiPasteurMemberus-gaap:MeasurementInputDiscountRateMember2021-09-3000003101582020-01-012020-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2021-09-300000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2020-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2021-09-300000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2020-12-310000310158us-gaap:DevelopedTechnologyRightsMember2021-06-020000310158us-gaap:LicenseMember2021-06-02mrk:case0000310158mrk:FosamaxMember2021-09-300000310158mrk:FederalMembermrk:FosamaxMembermrk:FemurFractureLitigationMember2014-03-012014-03-31mrk:claim0000310158mrk:JanuviaMember2021-09-300000310158mrk:JanuviaMembermrk:OtherStateCourtMember2021-09-300000310158mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMembermrk:JanuviaMember2021-09-300000310158mrk:ZetiaantitrustlitigationMember2021-09-300000310158mrk:BridionMemberus-gaap:PatentsMember2021-01-012021-09-300000310158us-gaap:PatentsMembermrk:JanuviaAndJanumetMember2021-01-012021-09-300000310158mrk:LegalDefenseCostsMember2021-09-300000310158mrk:LegalDefenseCostsMember2020-12-310000310158us-gaap:CommonStockMember2020-06-300000310158us-gaap:AdditionalPaidInCapitalMember2020-06-300000310158us-gaap:RetainedEarningsMember2020-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000310158us-gaap:TreasuryStockMember2020-06-300000310158us-gaap:NoncontrollingInterestMember2020-06-3000003101582020-06-300000310158us-gaap:RetainedEarningsMember2020-07-012020-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000310158us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000310158us-gaap:TreasuryStockMember2020-07-012020-09-300000310158us-gaap:NoncontrollingInterestMember2020-07-012020-09-300000310158us-gaap:CommonStockMember2020-09-300000310158us-gaap:AdditionalPaidInCapitalMember2020-09-300000310158us-gaap:RetainedEarningsMember2020-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000310158us-gaap:TreasuryStockMember2020-09-300000310158us-gaap:NoncontrollingInterestMember2020-09-300000310158us-gaap:CommonStockMember2021-06-300000310158us-gaap:AdditionalPaidInCapitalMember2021-06-300000310158us-gaap:RetainedEarningsMember2021-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000310158us-gaap:TreasuryStockMember2021-06-300000310158us-gaap:NoncontrollingInterestMember2021-06-3000003101582021-06-300000310158us-gaap:RetainedEarningsMember2021-07-012021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000310158us-gaap:TreasuryStockMember2021-07-012021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000310158us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000310158us-gaap:CommonStockMember2021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-09-300000310158us-gaap:RetainedEarningsMember2021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000310158us-gaap:TreasuryStockMember2021-09-300000310158us-gaap:NoncontrollingInterestMember2021-09-300000310158us-gaap:CommonStockMember2019-12-310000310158us-gaap:AdditionalPaidInCapitalMember2019-12-310000310158us-gaap:RetainedEarningsMember2019-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000310158us-gaap:TreasuryStockMember2019-12-310000310158us-gaap:NoncontrollingInterestMember2019-12-310000310158us-gaap:RetainedEarningsMember2020-01-012020-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000310158us-gaap:TreasuryStockMember2020-01-012020-09-300000310158us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000310158us-gaap:NoncontrollingInterestMember2020-01-012020-09-300000310158us-gaap:CommonStockMember2020-12-310000310158us-gaap:AdditionalPaidInCapitalMember2020-12-310000310158us-gaap:RetainedEarningsMember2020-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000310158us-gaap:TreasuryStockMember2020-12-310000310158us-gaap:NoncontrollingInterestMember2020-12-310000310158us-gaap:RetainedEarningsMember2021-01-012021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000310158us-gaap:TreasuryStockMember2021-01-012021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000310158us-gaap:NoncontrollingInterestMember2021-01-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-07-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-07-012020-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-07-012020-09-300000310158us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-01-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-01-012020-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-01-012020-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-3000003101582021-09-012021-09-3000003101582021-06-022021-06-020000310158srt:ScenarioForecastMember2021-10-012021-12-310000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberus-gaap:SegmentContinuingOperationsMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberus-gaap:SegmentDiscontinuedOperationsMember2021-01-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012020-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-30mrk:segment0000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:KeytrudaMember2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:KeytrudaMember2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:KeytrudaMember2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:KeytrudaMember2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:AlliancerevenueLynparzaMember2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:AlliancerevenueLynparzaMember2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:AlliancerevenueLynparzaMember2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:AlliancerevenueLynparzaMember2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMember2020-01-012020-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:LenvimaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:LenvimaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:LenvimaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:LenvimaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Member2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Member2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Member2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Member2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Member2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Member2020-01-012020-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:RotateqMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:RotateqMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:RotateqMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:RotateqMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:RotateqMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:VaqtaMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:BridionMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:BridionMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:BridionMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:BridionMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:PrevymisMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:PrevymisMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:PrevymisMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:PrevymisMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PrevymisMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:NoxafilMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:PrimaxinMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:PrimaxinMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:CancidasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:CancidasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:CancidasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:CancidasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMember2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMember2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMember2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMember2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:InvanzMember2020-01-012020-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:ZerbaxaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:ZerbaxaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:SimponiMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:SimponiMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:SimponiMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:SimponiMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:RemicadeMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMembermrk:BelsomraMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:IsentressIsentressHDMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:IsentressIsentressHDMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:AllianceRevenueAdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:AllianceRevenueAdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AllianceRevenueAdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:AdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:AdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:AdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:AdempasMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AdempasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:JanuviaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:JanuviaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:JanuviaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:JanuviaMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:JanumetMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:JanumetMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:JanumetMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:JanumetMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:OtherPharmaceuticalMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:OtherPharmaceuticalMembermrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:LivestockMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:CompanionAnimalsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:CompanionAnimalsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:CompanionAnimalsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:USmrk:CompanionAnimalsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158us-gaap:AllOtherSegmentsMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158us-gaap:AllOtherSegmentsMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158us-gaap:AllOtherSegmentsMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158us-gaap:AllOtherSegmentsMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158us-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158us-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158us-gaap:CorporateNonSegmentMembercountry:US2021-07-012021-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158us-gaap:CorporateNonSegmentMembercountry:US2020-07-012020-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2020-07-012020-09-300000310158us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000310158us-gaap:CorporateNonSegmentMembercountry:US2021-01-012021-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158us-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158us-gaap:CorporateNonSegmentMembercountry:US2020-01-012020-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2020-01-012020-09-300000310158us-gaap:CorporateNonSegmentMember2020-01-012020-09-300000310158country:US2021-07-012021-09-300000310158mrk:InternationalMember2021-07-012021-09-300000310158country:US2020-07-012020-09-300000310158mrk:InternationalMember2020-07-012020-09-300000310158country:US2021-01-012021-09-300000310158mrk:InternationalMember2021-01-012021-09-300000310158country:US2020-01-012020-09-300000310158mrk:InternationalMember2020-01-012020-09-300000310158us-gaap:EMEAMember2021-07-012021-09-300000310158us-gaap:EMEAMember2020-07-012020-09-300000310158us-gaap:EMEAMember2021-01-012021-09-300000310158us-gaap:EMEAMember2020-01-012020-09-300000310158country:CN2021-07-012021-09-300000310158country:CN2020-07-012020-09-300000310158country:CN2021-01-012021-09-300000310158country:CN2020-01-012020-09-300000310158country:JP2021-07-012021-09-300000310158country:JP2020-07-012020-09-300000310158country:JP2021-01-012021-09-300000310158country:JP2020-01-012020-09-300000310158srt:AsiaPacificMember2021-07-012021-09-300000310158srt:AsiaPacificMember2020-07-012020-09-300000310158srt:AsiaPacificMember2021-01-012021-09-300000310158srt:AsiaPacificMember2020-01-012020-09-300000310158srt:LatinAmericaMember2021-07-012021-09-300000310158srt:LatinAmericaMember2020-07-012020-09-300000310158srt:LatinAmericaMember2021-01-012021-09-300000310158srt:LatinAmericaMember2020-01-012020-09-300000310158mrk:OtherCountriesMember2021-07-012021-09-300000310158mrk:OtherCountriesMember2020-07-012020-09-300000310158mrk:OtherCountriesMember2021-01-012021-09-300000310158mrk:OtherCountriesMember2020-01-012020-09-300000310158us-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000310158us-gaap:MaterialReconcilingItemsMember2020-07-012020-09-300000310158us-gaap:MaterialReconcilingItemsMember2021-01-012021-09-300000310158us-gaap:MaterialReconcilingItemsMember2020-01-012020-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
2000 Galloping Hill Road
KenilworthNew Jersey07033
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes     No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No 
The number of shares of common stock outstanding as of the close of business on October 31, 2021: 2,525,943,936





Table of Contents





Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Sales$13,154 $10,929 $35,183 $30,570 
Costs, Expenses and Other
Cost of sales3,450 3,013 9,752 8,589 
Selling, general and administrative2,336 2,060 6,804 6,336 
Research and development2,445 3,349 9,177 7,609 
Restructuring costs107 113 487 265 
Other (income) expense, net(450)(312)(1,007)(637)
 7,888 8,223 25,213 22,162 
Income from Continuing Operations Before Taxes5,266 2,706 9,970 8,408 
Taxes on Income from Continuing Operations695 380 1,436 1,271 
Net Income from Continuing Operations4,571 2,326 8,534 7,137 
Less: Net Income Attributable to Noncontrolling Interests4 2 9 1 
Net Income from Continuing Operations Attributable to Merck & Co., Inc.4,567 2,324 8,525 7,136 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 617 766 2,025 
Net Income Attributable to Merck & Co. Inc.$4,567 $2,941 $9,291 $9,161 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.81 $0.92 $3.37 $2.82 
Income from Discontinued Operations 0.24 0.30 0.80 
Net Income$1.81 $1.16 $3.67 $3.62 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.80 $0.92 $3.36 $2.81 
Income from Discontinued Operations 0.24 0.30 0.80 
Net Income$1.80 $1.16 $3.66 $3.61 
 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Net Income Attributable to Merck & Co., Inc.$4,567 $2,941 $9,291 $9,161 
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized gain (loss) on derivatives, net of reclassifications84 (137)324 (153)
Net unrealized loss on investments, net of reclassifications   (18)
Benefit plan net gain and prior service credit, net of amortization
38 62 1,522 161 
Cumulative translation adjustment
(84)85 (251)(180)
 38 10 1,595 (190)
Comprehensive Income Attributable to Merck & Co., Inc.$4,605 $2,951 $10,886 $8,971 
 The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -



MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
September 30, 2021December 31, 2020
Assets
Current Assets
Cash and cash equivalents
$10,016 $8,050 
Accounts receivable (net of allowance for doubtful accounts of $69 in 2021
 and $67 in 2020)
8,571 6,803 
Inventories (excludes inventories of $2,373 in 2021 and $2,070 in 2020
classified in Other assets - see Note 7)
5,603 5,554 
Other current assets
6,868 4,674 
Current assets of discontinued operations 2,683 
Total current assets31,058 27,764 
Investments435 785 
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,155
in 2021 and $18,162 in 2020
18,565 17,000 
Goodwill18,862 18,882 
Other Intangibles, Net13,384 14,101 
Other Assets11,190 9,881 
Noncurrent Assets of Discontinued Operations 3,175 
 $93,494 $91,588 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt
$3,534 $6,431 
Trade accounts payable
3,366 4,327 
Accrued and other current liabilities
14,214 12,212 
Income taxes payable
954 1,597 
Dividends payable
1,660 1,674 
Current liabilities of discontinued operations 1,086 
Total current liabilities23,728 27,327 
Long-Term Debt22,907 25,360 
Deferred Income Taxes1,527 1,005 
Other Noncurrent Liabilities9,469 12,306 
Noncurrent Liabilities of Discontinued Operations 186 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2021 and 2020
1,788 1,788 
Other paid-in capital
44,149 39,588 
Retained earnings
51,691 47,362 
Accumulated other comprehensive loss
(4,590)(6,634)
93,038 82,104 
Less treasury stock, at cost:
1,051,780,149 shares in 2021 and 1,046,877,695 shares in 2020
57,244 56,787 
Total Merck & Co., Inc. stockholders’ equity35,794 25,317 
Noncontrolling Interests69 87 
Total equity35,863 25,404 
 $93,494 $91,588 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -



MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 Nine Months Ended
September 30,
 20212020
Cash Flows from Operating Activities
Net income from continuing operations$8,534 $7,137 
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Amortization1,231 1,393 
Depreciation1,148 1,210 
Intangible asset impairment charges 35 
Income from investments in equity securities, net(1,535)(964)
Charge for the acquisition of Pandion Therapeutics, Inc.1,556  
Deferred income taxes
28 32 
Share-based compensation
360 329 
Other
499 519 
Net changes in assets and liabilities
(3,794)(5,484)
Net Cash Provided by Operating Activities from Continuing Operations8,027 4,207 
Cash Flows from Investing Activities
Capital expenditures(3,240)(2,998)
Purchases of securities and other investments(1)(78)
Proceeds from sales of securities and other investments497 1,894 
Acquisition of Pandion Therapeutics, Inc. net of cash acquired(1,554) 
Acquisition of ArQule, Inc., net of cash acquired (2,545)
Other acquisitions, net of cash acquired(89)(907)
Other15 138 
Net Cash Used in Investing Activities from Continuing Operations(4,372)(4,496)
Cash Flows from Financing Activities
Net change in short-term borrowings(3,983)(311)
Payments on debt(1,153)(1,954)
Distribution from Organon & Co.9,000  
Proceeds from issuance of debt 4,419 
Purchases of treasury stock(822)(1,281)
Dividends paid to stockholders(4,967)(4,673)
Proceeds from exercise of stock options68 68 
Other(253)(472)
Net Cash Used in Financing Activities from Continuing Operations(2,110)(4,204)
Discontinued Operations
Net cash provided by operating activities1,051 2,040 
Net cash used in investing activities(134)(169)
Net cash used in financing activities(504) 
Net Cash Flows Provided by Discontinued Operations413 1,871 
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash(65)89 
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash1,893 (2,533)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted
cash of $103 at January 1, 2021 included in Other Assets)
8,153 9,934 
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash
of $30 at September 30, 2021 included in Other Assets)
$10,046 $7,401 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -

Notes to Condensed Consolidated Financial Statements (unaudited)

1.Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2021.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).
Recently Adopted Accounting Standards
In December 2019, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities, clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination, and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s consolidated financial statements upon adoption.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The Company adopted the new guidance effective January 1, 2021. There was no impact to the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards Not Yet Adopted
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In August 2020, the FASB issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The amended guidance is effective for interim and annual periods in 2022. Early adoption is permitted. The application of the amendments in the new guidance are to be applied either on a modified retrospective or a retrospective basis. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
- 6 -

Notes to Condensed Consolidated Financial Statements (unaudited)
2. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck will provide Organon various services and, similarly, Organon will provide Merck various services. The provision of services under the TSA agreement generally will terminate within 25 months following the spin-off. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck will continue to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck will continue operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck will (a) manufacture and supply certain active pharmaceutical ingredients for Organon, (b) toll manufacture and supply certain formulated pharmaceutical products for Organon, and (c) package and label certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon will (a) manufacture and supply certain formulated pharmaceutical products for Merck, and (b) package and label certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
Amounts included in the condensed consolidated statement of income for the above agreements were immaterial in the third quarter and first nine months of 2021. The amount due from Organon under the above agreements was $1.4 billion at September 30, 2021 and is reflected in Other current assets. The amount due to Organon under these agreements was $930 million at September 30, 2021 and is included in Accrued and other current liabilities.
The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s condensed consolidated statement of income as Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests through June 2, 2021, the date of the spin-off. Prior periods have been recast to reflect this presentation. As a result of the spin-off of Organon, Merck incurred separation costs of $556 million in the nine months ended September 30, 2021, and $193 million and $483 million in the three and nine months ended September 30, 2020, respectively, which are also included in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. As of December 31, 2020, the assets and liabilities associated with these businesses are classified as assets and liabilities of discontinued operations in the condensed consolidated balance sheet.

- 7 -

Notes to Condensed Consolidated Financial Statements (unaudited)
Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
 Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2020
2021 (1)
2020
Sales$1,622 $2,512 $4,911 
Costs, Expenses and Other
Cost of sales468 789 1,362 
Selling, general and administrative390 877 1,046 
Research and development41 103 113 
Restructuring costs1 1 4 
Other (income) expense, net (15)7 
900 1,755 2,532 
Income from discontinued operations before taxes722